Liquidia receives FDA Fast Track for YUTREPIA in systemic sclerosis–related Raynaud's

Liquidia received FDA Fast Track designation for YUTREPIA to treat systemic sclerosis–related Raynaud's phenomenon, enabling expedited development and regulatory review. The company plans to start a Phase 2a study in October 2026, aiming to address an estimated 30,000 U.S. patients with moderate-to-severe disease.

This Wire brief sits within Fusion42's coverage of Biotech.